menu
    • menu

    Find Nimodipine manufacturers, exporters & distributors on PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    13

    API Suppliers

    API Suppliers

    8

    USDMF

    US DMFs Filed

    4

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    2

    EU WC

    EU WC

    1

    KDMF

    KDMF

    7

    NDC API

    NDC API

    0

    VMF

    NDC API

    7

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 323

    MARKET PLACE

    9

    API

    3

    FDF

    2INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    53

    FDF Dossiers

    FDF Dossiers

    11

    FDA Orange Book

    FDA (Orange Book)

    31

    Europe

    Europe

    1

    Canada

    Canada

    0

    Australia

    Australia

    2

    South Africa

    South Africa

    8

    Listed Dossiers

    Listed Dossiers

    14DRUGS IN DEVELOPMENT

    FDF DossiersDRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    3

    EDQM

    3

    USP

    0

    JP

    3

    Others

    PATENTS & EXCLUSIVITIES

    6

    US Patents

    0

    US Exclusivities

    1

    Health Canada Patents

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    12

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    1,240,196

    Annual Reports

    NA

    Finished Drug Prices

    Listed Dossiers

    139 RELATED EXCIPIENT COMPANIES

    239EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 66085-59-4, Nimotop, Periplum, Admon, Nimodipino, Nymalize
    Molecular Formula
    C21H26N2O7
    Molecular Weight
    418.4  g/mol
    InChI Key
    UIAGMCDKSXEBJQ-UHFFFAOYSA-N
    FDA UNII
    57WA9QZ5WH
    Nimodipine
    A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
    Nimodipine is a Dihydropyridine Calcium Channel Blocker. The mechanism of action of nimodipine is as a Calcium Channel Antagonist.
    1 2D Structure

    Nimodipine

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
    2.1.2 InChI
    InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3
    2.1.3 InChI Key
    UIAGMCDKSXEBJQ-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC
    2.2 Other Identifiers
    2.2.1 UNII
    57WA9QZ5WH
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Admon

    2. Bay E 9736

    3. Bayvit, Nimodipino

    4. Brainal

    5. Calnit

    6. E 9736, Bay

    7. Hexal, Nimodipin

    8. Kenesil

    9. Modus

    10. Nimodipin Hexal

    11. Nimodipin Isis

    12. Nimodipin-isis

    13. Nimodipino Bayvit

    14. Nimotop

    15. Nymalize

    16. Remontal

    2.3.2 Depositor-Supplied Synonyms

    1. 66085-59-4

    2. Nimotop

    3. Periplum

    4. Admon

    5. Nimodipino

    6. Nymalize

    7. Bay E 9736

    8. Nimodipinum

    9. Bay-e 9736

    10. Nimodipinum [inn-latin]

    11. Nimodipino [inn-spanish]

    12. Bay-e-9736

    13. Nemotan

    14. 3-isopropyl 5-(2-methoxyethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

    15. Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate

    16. Nimodipine Ap

    17. Chebi:7575

    18. Nimodipine (nimotop)

    19. 3,5-pyridinedicarboxylic Acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl Ester

    20. Nsc-758476

    21. 57wa9qz5wh

    22. Mls000863294

    23. 3-o-(2-methoxyethyl) 5-o-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

    24. 3-(2-methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

    25. Ncgc00015714-09

    26. Smr000058300

    27. Dsstox_cid_3370

    28. Dsstox_rid_76998

    29. Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate

    30. Dsstox_gsid_23370

    31. 2-methoxyethyl Propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

    32. Nimogel

    33. Drg-0139

    34. Nimotop(tm)

    35. 1-methylethyl 2-(methyloxy)ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

    36. 2,6-dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic Acid 3-beta-methoxyethyl Ester 5-isopropyl Ester

    37. Sr-01000075335

    38. Nimotop (tn)

    39. Einecs 266-127-0

    40. Unii-57wa9qz5wh

    41. Brn 0459792

    42. Nimovent

    43. Nimodipime,(s)

    44. Nimodipine [usan:usp:inn:ban]

    45. Nymalize (tn)

    46. Cas-66085-59-4

    47. Mfcd00153848

    48. Eg-1961

    49. Opera_id_14

    50. Spectrum_001880

    51. Nimodipine [mi]

    52. Specplus_000716

    53. Nimodipine (usp/inn)

    54. Nimodipine [inn]

    55. Nimodipine [jan]

    56. Prestwick0_000918

    57. Prestwick1_000918

    58. Prestwick2_000918

    59. Prestwick3_000918

    60. Spectrum2_001562

    61. Spectrum3_000766

    62. Spectrum4_000791

    63. Spectrum5_001687

    64. Nimodipine [usan]

    65. N-149

    66. Nimodipine [vandf]

    67. Nimodipine [mart.]

    68. Nimodipine [usp-rs]

    69. Nimodipine [who-dd]

    70. (+/-)-nimodipine

    71. Cbiol_001832

    72. Lopac0_000891

    73. Schembl34041

    74. Bspbio_000796

    75. Bspbio_001397

    76. Bspbio_002412

    77. Kbiogr_000117

    78. Kbiogr_001262

    79. Kbioss_000117

    80. Kbioss_002408

    81. Mls000069381

    82. Mls001076550

    83. Mls001424155

    84. Mls002154061

    85. Mls002172461

    86. Mls003899190

    87. Divk1c_006812

    88. Spectrum1503600

    89. Spbio_001464

    90. Spbio_002985

    91. Bpbio1_000876

    92. Gtpl2523

    93. Chembl3197349

    94. Dtxsid5023370

    95. Nimodipine [orange Book]

    96. Schembl22882841

    97. Kbio1_001756

    98. Kbio2_000117

    99. Kbio2_002403

    100. Kbio2_002685

    101. Kbio2_004971

    102. Kbio2_005253

    103. Kbio2_007539

    104. Kbio3_000233

    105. Kbio3_000234

    106. Kbio3_001632

    107. 3-isopropyl 5-(2-methoxyethyl)

    108. Brd8407

    109. Nimodipine [ep Monograph]

    110. Nimodipine [usp Impurity]

    111. Bio1_000118

    112. Bio1_000607

    113. Bio1_001096

    114. Bio2_000117

    115. Bio2_000597

    116. Hms1361f19

    117. Hms1570h18

    118. Hms1791f19

    119. Hms1922e04

    120. Hms1989f19

    121. Hms2052m05

    122. Hms2089h13

    123. Hms2093g11

    124. Hms2097h18

    125. Hms2234b05

    126. Hms3262d04

    127. Hms3266o22

    128. Hms3369g07

    129. Hms3394m05

    130. Hms3402f19

    131. Hms3411i12

    132. Hms3657i03

    133. Hms3675i12

    134. Hms3714h18

    135. Nimodipine [usp Monograph]

    136. Pharmakon1600-01503600

    137. 3,5-pyridinecarboxylic Acid 2-methoxyethyl 1-methylethyl Ester

    138. Act02628

    139. Albb-015317

    140. Amy40399

    141. Bcp21152

    142. Brd-8407

    143. Hy-b0265

    144. 2,6-dimethyl-4-(3-nitrophenyl)-

    145. Tox21_110202

    146. Tox21_500891

    147. Bbl028286

    148. Bdbm50101971

    149. Ca-211

    150. Ccg-39340

    151. Nsc758476

    152. S1747

    153. Stk642934

    154. Akos005174934

    155. Akos015852459

    156. Nimodipine - Cas 66085-59-4

    157. Nimodipine 100 Microg/ml In Methanol

    158. Tox21_110202_1

    159. Ac-8484

    160. Ccg-101085

    161. Db00393

    162. Ks-1304

    163. Lp00891

    164. Nc00335

    165. Nsc 758476

    166. Sdccgsbi-0050866.p004

    167. Idi1_033867

    168. Isopropyl 2-methoxyethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

    169. Ncgc00015714-04

    170. Ncgc00015714-05

    171. Ncgc00015714-06

    172. Ncgc00015714-07

    173. Ncgc00015714-08

    174. Ncgc00015714-10

    175. Ncgc00015714-11

    176. Ncgc00015714-12

    177. Ncgc00015714-13

    178. Ncgc00015714-16

    179. Ncgc00015714-28

    180. Ncgc00021456-02

    181. Ncgc00024675-02

    182. Ncgc00024675-03

    183. Ncgc00024675-04

    184. Ncgc00024675-05

    185. Ncgc00024675-06

    186. Ncgc00024675-07

    187. Ncgc00024675-08

    188. Ncgc00024675-09

    189. Ncgc00261576-01

    190. Nimodipine 100 Microg/ml In Acetonitrile

    191. O5-isopropyl O3-(2-methoxyethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

    192. Smr002530605

    193. Sbi-0050866.p003

    194. Ab00513963

    195. Eu-0100891

    196. Ft-0602600

    197. N0896

    198. Sw219238-1

    199. C07267

    200. D00438

    201. F20554

    202. 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-

    203. Ab00053314-03

    204. Ab00053314-04

    205. Ab00053314_05

    206. Ab00053314_06

    207. 085n594

    208. Q421429

    209. Sr-01000075335-1

    210. Sr-01000075335-2

    211. Sr-01000075335-4

    212. Sr-01000075335-5

    213. Sr-01000075335-7

    214. Brd-a58048407-001-06-3

    215. Brd-a58048407-001-09-7

    216. Bay E 9736 Pound>> Bay-e-9736 Pound>> Baye97

    217. Nimodipine, British Pharmacopoeia (bp) Reference Standard

    218. Nimodipine, European Pharmacopoeia (ep) Reference Standard

    219. Nimodipine, United States Pharmacopeia (usp) Reference Standard

    220. Nimodipine, Pharmaceutical Secondary Standard; Certified Reference Material

    221. Nimodipine For Peak Identification, Europepharmacopoeia (ep) Reference Standard

    222. 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic Acid 2-methyloxyethyl 1-methylethyl Ester

    223. 2-methoxyethyl 1-methylethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate

    224. 3,5-pyridinedicarboxylic Acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-(2-methoxyethyl) 5-(1-methylethyl) Ester

    225. 3,5-pyridinedicarboxylic Acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,?2-methoxyethyl 1-methylethyl Ester

    226. 3-isopropyl 5-(2-methoxyethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate #

    227. 3-isopropyl5-(2-methoxyethyl)2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

    228. Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate

    229. O5-(2-methoxyethyl) O3-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

    2.4 Create Date
    2005-03-25
    3 Chemical and Physical Properties
    Molecular Weight 418.4 g/mol
    Molecular Formula C21H26N2O7
    XLogP33.1
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count8
    Rotatable Bond Count9
    Exact Mass418.17400117 g/mol
    Monoisotopic Mass418.17400117 g/mol
    Topological Polar Surface Area120 Ų
    Heavy Atom Count30
    Formal Charge0
    Complexity736
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count1
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 4  
    Drug NameNimodipine
    PubMed HealthNimodipine (By mouth)
    Drug ClassesCardiovascular Agent
    Drug LabelNimodipine belongs to the class of pharmacological agents known as calcium channel blockers. Nimodipine is isopropyl 2 - methoxyethyl 1, 4 - dihydro - 2, 6 - dimethyl - 4 - (m-nitrophenyl) - 3, 5 pyridinedicarboxylate.It has a molecular weight...
    Active IngredientNimodipine
    Dosage FormCapsule
    RouteOral
    Strength30mg
    Market StatusPrescription
    CompanyThepharmanetwork; Sun Pharm Inds; Barr Labs; Banner Pharmacaps

    2 of 4  
    Drug NameNymalize
    PubMed HealthNimodipine (By mouth)
    Drug ClassesCardiovascular Agent
    Drug LabelNYMALIZE contains nimodipine, a dihydropyridine calcium channel blocker. Nimodipine is isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate. It has a molecular weight of 418.5 and a molecular formula of C21H26...
    Active IngredientNimodipine
    Dosage FormSolution
    RouteOral
    Strength60mg/20ml
    Market StatusPrescription
    CompanyArbor Pharms

    3 of 4  
    Drug NameNimodipine
    PubMed HealthNimodipine (By mouth)
    Drug ClassesCardiovascular Agent
    Drug LabelNimodipine belongs to the class of pharmacological agents known as calcium channel blockers. Nimodipine is isopropyl 2 - methoxyethyl 1, 4 - dihydro - 2, 6 - dimethyl - 4 - (m-nitrophenyl) - 3, 5 pyridinedicarboxylate.It has a molecular weight...
    Active IngredientNimodipine
    Dosage FormCapsule
    RouteOral
    Strength30mg
    Market StatusPrescription
    CompanyThepharmanetwork; Sun Pharm Inds; Barr Labs; Banner Pharmacaps

    4 of 4  
    Drug NameNymalize
    PubMed HealthNimodipine (By mouth)
    Drug ClassesCardiovascular Agent
    Drug LabelNYMALIZE contains nimodipine, a dihydropyridine calcium channel blocker. Nimodipine is isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate. It has a molecular weight of 418.5 and a molecular formula of C21H26...
    Active IngredientNimodipine
    Dosage FormSolution
    RouteOral
    Strength60mg/20ml
    Market StatusPrescription
    CompanyArbor Pharms

    4.2 Drug Indication

    For use as an adjunct to improve neurologic outcome following subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms by reducing the incidence and severity of ischemic deficits.

    FDA Label

    Treatment of aneurysmal subarchnoidal haemorrhage

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Nimodipine belongs to the class of pharmacological agents known as calcium channel blockers. Nimodipine is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured congenital aneurysms who are in good neurological condition post-ictus (e.g., Hunt and Hess Grades I-III). The contractile processes of smooth muscle cells are dependent upon calcium ions, which enter these cells during depolarization as slow ionic transmembrane currents. Nimodipine inhibits calcium ion transfer into these cells and thus inhibits contractions of vascular smooth muscle. In animal experiments, nimodipine had a greater effect on cerebral arteries than on arteries elsewhere in the body perhaps because it is highly lipophilic, allowing it to cross the blood brain barrier.

    5.2 MeSH Pharmacological Classification

    Antihypertensive Agents

    Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)

    Calcium Channel Blockers

    A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)

    Vasodilator Agents

    Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)

    5.3 FDA Pharmacological Classification
    5.3.1 Active Moiety
    NIMODIPINE
    5.3.2 FDA UNII
    57WA9QZ5WH
    5.3.3 Pharmacological Classes
    Dihydropyridine Calcium Channel Blocker [EPC]; Dihydropyridines [CS]; Calcium Channel Antagonists [MoA]
    5.4 ATC Code

    C08CA06

    S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

    C - Cardiovascular system

    C08 - Calcium channel blockers

    C08C - Selective calcium channel blockers with mainly vascular effects

    C08CA - Dihydropyridine derivatives

    C08CA06 - Nimodipine

    5.5 Absorption, Distribution and Excretion

    Absorption

    In humans, nimodipine is rapidly absorbed after oral administration, and peak concentrations are generally attained within one hour. Bioavailability is 100% following intravenous administration and 3-30% following oral administration due to extensive first-pass metabolism.

    Route of Elimination

    Nimodipine is eliminated almost exclusively in the form of metabolites and less than 1% is recovered in the urine as unchanged drug. Numerous metabolites, all of which are either inactive or considerably less active than the parent compound, have been identified.

    5.6 Metabolism/Metabolites

    Hepatic metabolism via CYP 3A4.

    Nimodipine has known human metabolites that include 2,6-Dimethyl-4-(3-nitrophenyl)-5-propan-2-yloxycarbonyl-1,4-dihydropyridine-3-carboxylic acid, Dehydro nimodipine, and Unii-96S4GG1upr.

    S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560

    5.7 Biological Half-Life

    1.7-9 hours

    5.8 Mechanism of Action

    Although the precise mechanism of action is not known, nimodipine blocks intracellular influx of calcium through voltage-dependent and receptor-operated slow calcium channels across the membranes of myocardial, vascular smooth muscle, and neuronal cells. By specifically binding to L-type voltage-gated calcium channels, nimodipine inhibits the calcium ion transfer, resulting in the inhibition of vascular smooth muscle contraction. Evidence suggests that the dilation of small cerebral resistance vessels, with a resultant increase in collateral circulation, and/or a direct effect involving the prevention of calcium overload in neurons may be responsible for nimodipine's clinical effect in patients with subarachnoid hemorrhage.

    API SUPPLIERS

    read-more
    read-more

    01

    Biophore India Pharmaceuticals Pvt...

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    iPHEX India
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF arrow-down Click Us! arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 34203

    Submission : 2019-12-03

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R0-CEP 2020-353 - Rev 00

    Issue Date : 2022-10-25

    Type : Chemical

    Substance Number : 1245

    Status : Valid

     JDMF EU-WC NDC KDMF VMF Others AUDIT
    Biophore

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    UQUIFA

    Spain

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AES 2024
    Not Confirmed
    arrow

    UQUIFA

    Spain

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AES 2024
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2018-05-31

    Pay. Date : 2018-05-10

    DMF Number : 16951

    Submission : 2003-11-03

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2004-272 - Rev 03

    Issue Date : 2023-10-04

    Type : Chemical

    Substance Number : 1245

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 49711-0104

    Start Marketing Date : 2009-10-23

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

     KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Lusochimica

    Italy

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AES 2024
    Not Confirmed
    arrow

    Lusochimica

    Italy

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AES 2024
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2019-12-18

    Pay. Date : 2017-06-07

    DMF Number : 14979

    Submission : 2000-07-26

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2022-403 - Rev 00

    Issue Date : 2024-01-24

    Type : Chemical

    Substance Number : 1245

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 43898-0117

    Start Marketing Date : 2000-07-26

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

     KDMF arrow-down
    ✖

    Registrant Name : Samoh Pharmaceutical Co., Ltd.

    Registration Date : 2021-03-10

    Registration Number : 20210310-209-J-534

    Manufacturer Name : Lusochimica SpA

    Manufacturer Address : Via Giotto 9, 23871 Lomagna (LC), Italy

     VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Dasami Lab

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AES 2024
    Not Confirmed
    arrow

    Dasami Lab

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AES 2024
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2019-02-15

    Pay. Date : 2018-10-26

    DMF Number : 32971

    Submission : 2018-10-01

    Status : Active

    Type : II

     CEP/COS JDMF EU-WCarrow-down
    ✖

    Date of Issue : 2024-02-19

    Valid Till : 2027-02-19

    Written Confirmation Number : WC-0578

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 70966-0012

    Start Marketing Date : 2008-01-17

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

     KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Bayer AG

    Germany

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AES 2024
    Not Confirmed
    arrow

    Bayer AG

    Germany

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AES 2024
    Not Confirmed
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 4664

    Submission : 1982-09-08

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Bayer AG

    Germany

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AES 2024
    Not Confirmed
    arrow

    Bayer AG

    Germany

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AES 2024
    Not Confirmed
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 4816

    Submission : 1982-12-22

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Catalent Pharma Solutions

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AES 2024
    Not Confirmed
    arrow

    Catalent Pharma Solutions

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AES 2024
    Not Confirmed
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 15598

    Submission : 2001-08-27

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Catalent Pharma Solutions

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AES 2024
    Not Confirmed
    arrow

    Catalent Pharma Solutions

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AES 2024
    Not Confirmed
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 18373

    Submission : 2005-05-24

    Status : Inactive

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Siegfried AG

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AES 2024
    Not Confirmed
    arrow

    Siegfried AG

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AES 2024
    Not Confirmed
    USDMF CEP/COS Inactive-api
    ✖

    Certificate Number : R0-CEP 1999-105 - Rev 02

    Issue Date : 2004-12-06

    Type : Chemical

    Substance Number : 1245

    Status : Withdrawn by Holder

     JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    DEAFARMA

    Italy

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    AES 2024
    Not Confirmed
    arrow

    DEAFARMA

    Italy

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AES 2024
    Not Confirmed
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Listed Suppliers

    read-more
    read-more

    01

    Biophore India Pharmaceuticals Pvt ...

    India
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Nimodipine

    About the Company : Biophore, founded in 2007, has established itself as a reliable partner in the development and manufacturing of niche and complex pharmaceutical products. With 4 USFDA and EU-appro...

    Biophore, founded in 2007, has established itself as a reliable partner in the development and manufacturing of niche and complex pharmaceutical products. With 4 USFDA and EU-approved API manufacturing facilities, a dedicated intermediate facility, and a R&D laboratory housing 400 scientists, Biophore has positioned itself as a global leader among API companies. It consistently ranks among the top 10 US DMF filers and has obtained over 150 patents worldwide in process and polymorph areas. Biophore's facilities have an impressive track record of successful audits by regulatory bodies such as USFDA, EMEA, ANVISA, COFEPRIS, and WHO GMP.
    Biophore

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Dasami Lab

    India
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Dasami Lab

    India
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Nimodipine

    About the Company : Dasami Lab Private Limited incorporated with MCA on 24 July 2015. The Dasami Lab Private Limited is listed in the class of pvtltd company and classified as Non Govt Company. This c...

    Dasami Lab Private Limited incorporated with MCA on 24 July 2015. The Dasami Lab Private Limited is listed in the class of pvtltd company and classified as Non Govt Company. This company is registered at Registrar of Companies(ROC), Hyderabad with an Authorized Share Capital of Rs. 110 CR and its paid up capital is 110 CR.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    DEAFARMA

    Italy
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    DEAFARMA

    Italy
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Italy
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Nimodipine

    About the Company : In the dinamic pharmaceutical field, DEAFARMA is the reference point for primaries Pharmaceutical Laboratories for over twenty years, even in the national and international territo...

    In the dinamic pharmaceutical field, DEAFARMA is the reference point for primaries Pharmaceutical Laboratories for over twenty years, even in the national and international territory. DEAFARMA works with success in the pharmaceutical raw materials field through Agencies and professional relations with the most important European and Asiatic factories. Our partners are well known, reliable producers and all of them are operating in accordance with the latest GMP Rules. The APIs mentioned in the DEAFARMA catalogue are always supported by DMF and/or CEP.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Hetero Drugs

    India
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Hetero Drugs

    India
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Nimodipine

    About the Company : Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & F...

    Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & Finished Dosages. Ever since its establishment in 1993, Hetero showed a tradition of excellence and deep sense of commitment in developing cost effective processes to offer wide range of affordable drugs. Hetero is building on the strengths of vertical integration in discovery research, process chemistry, API manufacturing, formulation development and commercialization.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Lusochimica

    Italy
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Lusochimica

    Italy
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Italy
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Nimodipine

    About the Company : Lusochimica S.p.A., part of the Menarini Group since 1984, is specialized in manufacturing bulk active pharmaceutical ingredients (API) at facilities in Lomagna, Lodi and Pisa, Ita...

    Lusochimica S.p.A., part of the Menarini Group since 1984, is specialized in manufacturing bulk active pharmaceutical ingredients (API) at facilities in Lomagna, Lodi and Pisa, Italy. Founded in 1964, Lusochimica is committed to stringent cGMP standards and ensures the highest Italian quality in API production. Our mission centers on employing cutting-edge technology to reliably supply superior active ingredients that uphold the safety and efficacy of pharmaceutical products.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Shandong Xinhua Pharmaceutical

    China
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    Shandong Xinhua Pharmaceutical

    China
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Nimodipine

    About the Company : Established in 1943 as one of the national largest manufacturing and exporting bases in the chemical synthetic pharmaceuticals field, Shandong Xinhua Pharmaceutical Company Limited...

    Established in 1943 as one of the national largest manufacturing and exporting bases in the chemical synthetic pharmaceuticals field, Shandong Xinhua Pharmaceutical Company Limited ("Shandong Xinhua") is a leading position in the manufacturing technology and capacity for antipyretics and analgesics in China and is an important manufacturer in China for the drugs for central nervous system, steroids, cardio cerebrovascular system as well as finished dosage forms and pharmaceutical intermediates.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    UQUIFA

    Spain
    Medlab Asia & Asia Health
    Not Confirmed
    arrow

    UQUIFA

    Spain
    arrow
    Medlab Asia & Asia Health
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Spain
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Nimodipine

    About the Company : With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built o...

    With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built on a quality manufacturing platform and a strong track record of service and reliability. Uquifa Group manufactures Active Pharmaceutical Ingredients (APIs) and intermediates for the global pharmaceutical and animal health industries.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"NIMODIPINE","year":"2021","qtr":"Q1","strtotime":1614018600,"product":"NIMODIPINE","address":"105 AATISH ANNEXIE GULBAI TEKRAOFF. C.F. ROAD","city":"AHMEDABAD","supplier":"SUSHEN MEDICAMENTOS PVT. LTD","supplierCountry":"INDIA","foreign_port":"TASHKENT","customer":"OOO SHARQ DARMON","customerCountry":"UZBEKISTAN","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"349.8","totalValueFC":"1730.6","currency":"USD","unitRateINR":25200.002,"date":"23-Feb-2021","totalValueINR":"126000.01","totalValueInUsd":"1730.6","indian_port":"AHMEDABAD AIR","hs_no":"29333990","bill_no":"8872036","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UZBEKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"105 AATISH ANNEXIE GULBAI TEKRAOFF. C.F. ROAD, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"NIMODIPINE","year":"2021","qtr":"Q1","strtotime":1614709800,"product":"NIMODIPINE BP BATCH NO ; LF-NIMO\/012021\/003 CAS NO ; 66085-59-4","address":"4, RIDHI SIDHI BUNGLOWS, GOPI - AKSHAR FARM ROAD,","city":"ANAND","supplier":"LAKSH FINECHEM PVT ","supplierCountry":"INDIA","foreign_port":"COLOMBO","customer":"STATE PHARMACEUTICALS MANUFACTURING","customerCountry":"SRI LANKA","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"331.2","totalValueFC":"1638.7","currency":"USD","unitRateINR":23859.792000000001,"date":"03-Mar-2021","totalValueINR":"119298.96","totalValueInUsd":"1638.7","indian_port":"AHMEDABAD AIR","hs_no":"29333990","bill_no":"9067529","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"SRI LANKA","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"4, RIDHI SIDHI BUNGLOWS, GOPI - AKSHAR FARM ROAD,, ANAND","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q2","strtotime":1623177000,"product":"NIMODIPINE USP 43","address":"4, RIDHI SIDHI BUNGLOWS, GOPI - AKSHAR FARM ROAD,","city":"ANAND","supplier":"LAKSH FINE CHEM PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"ASUNCION","customer":"QUIMFA S.A","customerCountry":"PARAGUAY","quantity":"60.00","actualQuantity":"60","unit":"KGS","unitRateFc":"289.6","totalValueFC":"17022.7","currency":"USD","unitRateINR":20865.799999999999,"date":"09-Jun-2021","totalValueINR":"1251948","totalValueInUsd":"17022.7","indian_port":"AHMEDABAD AIR","hs_no":"29333990","bill_no":"2295697","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"PARAGUAY","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"4, RIDHI SIDHI BUNGLOWS, GOPI - AKSHAR FARM ROAD,, ANAND","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1629743400,"product":"NIMODIPINE BP (MICRONISED) MAKE: LAKSH F INECHEM PVT LTD BATCH NO.LF-NIMO\/032021\/ 005 MFG DT.MAR-2021 EXP DT.FEB-2024","address":"3, BOTAWALA BLDG., 1ST FLOOR, BANK STREET, BEHIND SBI, FORT","city":"MUMBAI","supplier":"NISHCHEM INTERNATIONAL PVT. LTD","supplierCountry":"INDIA","foreign_port":"BIRGUNJ","customer":"MAGNUS PHARMA PVT","customerCountry":"NEPAL","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"416.4","totalValueFC":"404.5","currency":"USD","unitRateINR":30000,"date":"24-Aug-2021","totalValueINR":"30000","totalValueInUsd":"404.5","indian_port":"RAXAUL","hs_no":"29333990","bill_no":"4075898","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"NEPAL","selfForZScoreResived":"Micronized","supplierPort":"RAXAUL","supplierAddress":"3, BOTAWALA BLDG., 1ST FLOOR, BANK STREET, BEHIND SBI, FORT, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1650825000,"product":"NIMODIPINE BP","address":"1007 HUBTOWN SOLARIS,,10TH FLOOR, N.S. PHADKE MARG, NR.","city":"EAST WEST FLYOVER ANDHERI EAST,MAHA","supplier":"ROOP RASAYAN INDUSTRIES PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"BIRGUNJ","customer":"MEERA BIOTECH PRIVATE ","customerCountry":"NEPAL","quantity":"15.00","actualQuantity":"15","unit":"KGS","unitRateFc":"21000","totalValueFC":"4175","currency":"INR","unitRateINR":21000,"date":"25-Apr-2022","totalValueINR":"315000","totalValueInUsd":"4175","indian_port":"RAXAUL","hs_no":"29333990","bill_no":"9947390","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"NEPAL","selfForZScoreResived":"Pharma Grade","supplierPort":"RAXAUL","supplierAddress":"1007 HUBTOWN SOLARIS,,10TH FLOOR, N.S. PHADKE MARG, NR., EAST WEST FLYOVER ANDHERI EAST,MAHA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1662402600,"product":"NIMODIPINE","address":"8-3-166\/182, A BLOCK, NORTH WING,, 105-108, IST FLOOR CHALLA ESTATES,","city":"ERRADADDA,TELANGANA","supplier":"DASAMI LAB PRIVATE ","supplierCountry":"INDIA","foreign_port":"MEXICO CITY","customer":"TO THE PORDER OF","customerCountry":"MEXICO","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"340","totalValueFC":"1597.2","currency":"USD","unitRateINR":25600,"date":"06-Sep-2022","totalValueINR":"128000","totalValueInUsd":"1597.2","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"4002995","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"MEXICO","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-166\/182, A BLOCK, NORTH WING,, 105-108, IST FLOOR CHALLA ESTATES,, ERRADADDA,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1663266600,"product":"NIMODIPINE BP (MICRONISED)","address":"3 BOTAWALA BLDG 1ST FLOOR,BANK STR EET BEHIND SBI FORT","city":"MUMBAI,MAHARASHTRA","supplier":"NISHCHEM INTERNATIONAL PVT. LTD","supplierCountry":"INDIA","foreign_port":"BIRGUNJ","customer":"TO THE ORDER OF MARUTI PHARMA P.LTD","customerCountry":"NEPAL","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"18500","totalValueFC":"461.7","currency":"INR","unitRateINR":18500,"date":"16-Sep-2022","totalValueINR":"37000","totalValueInUsd":"461.7","indian_port":"RAXAUL","hs_no":"29333990","bill_no":"4229505","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"NEPAL","selfForZScoreResived":"Micronized","supplierPort":"RAXAUL","supplierAddress":"3 BOTAWALA BLDG 1ST FLOOR,BANK STR EET BEHIND SBI FORT, MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1676485800,"product":"NIMODIPINE BP","address":"","city":"","supplier":"APOTECA PHARMA PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"MOSCOW DOMODEDOVO","customer":"TRIVIUM XXI LTD,","customerCountry":"RUSSIA","quantity":"0.10","actualQuantity":"100","unit":"GMS","unitRateFc":"0.2","totalValueFC":"24.2","currency":"EUR","unitRateINR":20,"date":"16-Feb-2023","totalValueINR":"2000","totalValueInUsd":"24.2","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"7825263","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1677781800,"product":"PHARMACEUTICAL RAW MATERIAL NIMODIPINE B","address":"309\/310, HARIKRUPA TOWER, NR. OLD SHARDA MANDIR CROSS ROAD, E","city":"AHMEDABAD","supplier":"JAI RADHE SALES","supplierCountry":"INDIA","foreign_port":"TASHKENT","customer":"TO THE ORDER OF","customerCountry":"UZBEKISTAN","quantity":"15.00","actualQuantity":"15","unit":"KGS","unitRateFc":"239","totalValueFC":"3161.1","currency":"USD","unitRateINR":17333.333333333332,"date":"03-Mar-2023","totalValueINR":"260000","totalValueInUsd":"3161.1","indian_port":"AHMEDABAD ICD","hs_no":"29333990","bill_no":"8215968","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UZBEKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD ICD","supplierAddress":"309\/310, HARIKRUPA TOWER, NR. OLD SHARDA MANDIR CROSS ROAD, E, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1678386600,"product":"NIMODIPINE","address":"SHOP NO. 4, TULJABHAWANI RESIDENCY, MAYUR PARK, HARSOOL,","city":"AURANGABAD , M.S.","supplier":"SWAPNROOP DRUGS AND PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"FRANKFURT\/MAIN INT\\'L","customer":"M\/S. RHEINISCHE-FRIEDRICH-WILHELMS-","customerCountry":"GERMANY","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"1300","totalValueFC":"413.4","currency":"EUR","unitRateINR":113333.33333333334,"date":"10-Mar-2023","totalValueINR":"34000","totalValueInUsd":"413.4","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"8370552","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"SHOP NO. 4, TULJABHAWANI RESIDENCY, MAYUR PARK, HARSOOL,, AURANGABAD , M.S.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1680719400,"product":"PHARMACEUTICAL RAW MATERIAL : NIMODIPINE","address":"4, RIDHI SIDHI BUNGLOWS, GOPI - AKSHAR FARM ROAD,","city":"ANAND","supplier":"LAKSH FINE CHEM PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"HO CHI MINH C","customer":"TO THE ORDER OF","customerCountry":"VIETNAM","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"250","totalValueFC":"695.5","currency":"USD","unitRateINR":19000,"date":"06-Apr-2023","totalValueINR":"57000","totalValueInUsd":"695.5","indian_port":"BOMBAY AIR","hs_no":"29333990","bill_no":"9107402","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"VIETNAM, DEMOCRATIC REP. OF","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"4, RIDHI SIDHI BUNGLOWS, GOPI - AKSHAR FARM ROAD,, ANAND","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1692124200,"product":"NIMODIPINE BP MICRONISED","address":"3 BOTAWALA BLDG. 1ST FLOOR BANK STREET BEHIND SBI FORT","city":"MUMBAI","supplier":"NISHCHEM INTERNATIONAL PVT. LTD","supplierCountry":"INDIA","foreign_port":"BIRGUNJ","customer":"Z TO ORDER AND NA","customerCountry":"NEPAL","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"30000","totalValueFC":"354.9","currency":"INR","unitRateINR":29399.643,"date":"16-Aug-2023","totalValueINR":"29399.643","totalValueInUsd":"354.9","indian_port":"RAXAUL","hs_no":"29333990","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"NEPAL","selfForZScoreResived":"Micronized","supplierPort":"RAXAUL","supplierAddress":"3 BOTAWALA BLDG. 1ST FLOOR BANK STREET BEHIND SBI FORT, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1695321000,"product":"NIMODIPINE BP (MICRONISED)","address":"3, BOTAWALA BLDG., 1ST FLOOR,","city":"FORT, MUMBAI MAHARASHTRA","supplier":"NISHCHEM INTERNATIONAL PVT. LTD","supplierCountry":"INDIA","foreign_port":"BIRGUNJ","customer":"TO THE ORDER OF","customerCountry":"NEPAL","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"30000","totalValueFC":"361.4","currency":"INR","unitRateINR":30000,"date":"22-Sep-2023","totalValueINR":"30000","totalValueInUsd":"361.4","indian_port":"Raxaul","hs_no":"29333990","bill_no":"4119527","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"NEPAL","selfForZScoreResived":"Micronized","supplierPort":"Raxaul","supplierAddress":"3, BOTAWALA BLDG., 1ST FLOOR,, FORT, MUMBAI MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1701628200,"product":"RAW MATERIAL USE IN PHARMACEUTICAL INDUSTRIES: NIMODIPINE USP BNO. LF-NIMO\/092023\/009 MFG DATE: SEP-23 EXP. DATE: AUG-26","address":"814, `DEVPATH`, BESIDE LAL BUNGLOW,","city":"C.G.ROAD\/ AHMEDABD\/GUJARAT","supplier":"ESPEE PHARMA CHEM ","supplierCountry":"INDIA","foreign_port":"ASUNCION","customer":"TO THE ORDER","customerCountry":"PARAGUAY","quantity":"15.00","actualQuantity":"15","unit":"KGS","unitRateFc":"350","totalValueFC":"4721.1","currency":"USD","unitRateINR":26200,"date":"04-Dec-2023","totalValueINR":"393000","totalValueInUsd":"4721.1","indian_port":"Ahmedabad Air","hs_no":"29333990","bill_no":"5777212","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"PARAGUAY","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"814, `DEVPATH`, BESIDE LAL BUNGLOW,, C.G.ROAD\/ AHMEDABD\/GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1710354600,"product":"API(ACTIVE PHARMACEUTICAL INGREDIENTS)RAW MATERIAL FOR USE IN PHARM.INDUSTRIES FOR HUMAN USE NIMODIPINE USP","address":"C-1009, SIDDHI VINAYAK TOWER, OFF. S.G HIGHWAY, MAKARBA","city":"AHMEDABAD","supplier":"CHEMFORTE INDIA PRIVATE ","supplierCountry":"INDIA","foreign_port":"MEXICO CITY","customer":"MEXICO","customerCountry":"MEXICO","quantity":"15.00","actualQuantity":"15","unit":"KGS","unitRateFc":"412","totalValueFC":"5984.2","currency":"USD","unitRateINR":33126.609333333334,"date":"14-Mar-2024","totalValueINR":"496899.14","totalValueInUsd":"5984.2","indian_port":"Ahmedabad Air","hs_no":"29333990","bill_no":"8315947","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"MEXICO","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"C-1009, SIDDHI VINAYAK TOWER, OFF. S.G HIGHWAY, MAKARBA, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1725388200,"product":"NIMODIPINE BP (MICRONISED)","address":"3, BOTAWALA BLDG., 1ST FLOOR,","city":"FORT, MUMBAI MAHARASHTRA","supplier":"NISHCHEM INTERNATIONAL PVT. LTD","supplierCountry":"INDIA","foreign_port":"BIRGUNJ","customer":"TO THE ORDER OF NATIONAL HEALTHCARE","customerCountry":"NEPAL","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"29000","totalValueFC":"1038.2","currency":"INR","unitRateINR":29000.006666666668,"date":"04-Sep-2024","totalValueINR":"87000.02","totalValueInUsd":"1038.2","indian_port":"Raxaul","hs_no":"29333990","bill_no":"3743711","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"NEPAL","selfForZScoreResived":"Micronized","supplierPort":"Raxaul","supplierAddress":"3, BOTAWALA BLDG., 1ST FLOOR,, FORT, MUMBAI MAHARASHTRA","customerAddress":""},{"dataSource":"API Import","activeIngredients":"NIMODIPINE","year":"2021","qtr":"Q1","strtotime":1610389800,"product":"NIMODIPINE MICRONIZED","address":"ALKEM HOUSE, DEVASHISH ADJACENT TOMATULYA CENTRE, SENAPATI BAPAT MARG","city":"LOWER PAREL, MUMBAI. MAHARASHTRA","supplier":"UNION QUIMICO FARMACEUTICA ","supplierCountry":"SPAIN","foreign_port":"BARCELONA","customer":"ALKEM LABORATORIES","customerCountry":"INDIA","quantity":"4.00","actualQuantity":"4","unit":"KGS","unitRateFc":"3000","totalValueFC":"12141.6","currency":"USD","unitRateINR":"222000","date":"12-Jan-2021","totalValueINR":"888000","totalValueInUsd":"12141.6","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"2320213","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Micronized","supplierPort":"BARCELONA","supplierAddress":"","customerAddress":"ALKEM HOUSE, DEVASHISH ADJACENT TOMATULYA CENTRE, SENAPATI BAPAT MARG"},{"dataSource":"API Import","activeIngredients":"NIMODIPINE","year":"2021","qtr":"Q1","strtotime":1612722600,"product":"NIMODIPINE USP ACTIVE PHARMACEUTICAL INGREDIENT-SAMPLE (1 BOTTLE 25G","address":"P NO.64&65, SY NO.342, ALEAP I E, GAJULARAMARAM (V), QUTBULLAPUR (M),","city":"HYDERABAD, AP.","supplier":"AMNEAL PHARMACEUTICALS","supplierCountry":"UNITED STATES","foreign_port":"NEW YORK - JOHN F. K","customer":"AIRISPHARMA PVT LTD","customerCountry":"INDIA","quantity":"0.03","actualQuantity":"0.025","unit":"KGS","unitRateFc":"750","totalValueFC":"19","currency":"USD","unitRateINR":"55350","date":"08-Feb-2021","totalValueINR":"1383.75","totalValueInUsd":"19","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"2665386","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"NEW YORK - JOHN F. K","supplierAddress":"","customerAddress":"P NO.64&65, SY NO.342, ALEAP I E, GAJULARAMARAM (V), QUTBULLAPUR (M),"},{"dataSource":"API Import","activeIngredients":"NIMODIPINE","year":"2021","qtr":"Q2","strtotime":1617820200,"product":"NIMODIPINE EP (BATCH NO.1910094 MFG.DATE-27\/10\/2019 EXP.DATE-27\/10\/2023)","address":"B-4\/160, SAFDARJUNG ENCLAVE","city":"NEW DELHI ,","supplier":"RULAND CHEMISTRY CO., LTD.","supplierCountry":"CHINA","foreign_port":"HANGCHOW (HANGZHOU)","customer":"SIMPEX PHARMA PRIVATE ","customerCountry":"INDIA","quantity":"60.00","actualQuantity":"60","unit":"KGS","unitRateFc":"245","totalValueFC":"14640.9","currency":"USD","unitRateINR":"18166.8","date":"08-Apr-2021","totalValueINR":"1090005","totalValueInUsd":"14640.9","indian_port":"DELHI AIR","hs_no":"29333100","bill_no":"3488184","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HANGCHOW (HANGZHOU)","supplierAddress":"","customerAddress":"B-4\/160, SAFDARJUNG ENCLAVE"},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1633285800,"product":"NIMODIPINE - CODE - 1672","address":"PLOT NO-2, SURVEY NO.93,SATYAM ENCLAVE,PETBASHEERABAD,QUTHUBLLAPUR","city":"MANDAL, HYDERABAD, ANDHRA PRADESH","supplier":"LUSOCHIMICA","supplierCountry":"ITALY","foreign_port":"NA","customer":"APPCURE LABS PVT LTD","customerCountry":"INDIA","quantity":"0.25","actualQuantity":"0.25","unit":"KGS","unitRateFc":"6000","totalValueFC":"1489.7","currency":"USD","unitRateINR":"446400","date":"04-Oct-2021","totalValueINR":"111600","totalValueInUsd":"1489.7","indian_port":"HYDERABAD AIR","hs_no":"29333990","bill_no":"5702735","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"PLOT NO-2, SURVEY NO.93,SATYAM ENCLAVE,PETBASHEERABAD,QUTHUBLLAPUR"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1658428200,"product":"1672 NIMODIPINE","address":"201, DEVAVRATA, SECTOR 17,,VASHI, NAVI MUMBAI,","city":"NAVI MUMBAI,MAHARASHTRA","supplier":"LUSOCHIMICA","supplierCountry":"ITALY","foreign_port":"NA","customer":"STRIDES PHARMA SCIENCE","customerCountry":"INDIA","quantity":"6.00","actualQuantity":"6","unit":"KGS","unitRateFc":"3000","totalValueFC":"18845.1","currency":"EUR","unitRateINR":"249750","date":"22-Jul-2022","totalValueINR":"1498500","totalValueInUsd":"18845.1","indian_port":"BANGALORE AIR","hs_no":"29333990","bill_no":"9667612","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"201, DEVAVRATA, SECTOR 17,,VASHI, NAVI MUMBAI,"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1724783400,"product":"NIMODIPINE EP","address":"B-4\/160, SAFDARJUNG ENCLAVE","city":"NEW DELHI ,","supplier":"RULAND CHEMISTRY CO., LTD.","supplierCountry":"CHINA","foreign_port":"BEIJING","customer":"SIMPEX PHARMA PRIVATE ","customerCountry":"INDIA","quantity":"20.00","actualQuantity":"20","unit":"KGS","unitRateFc":"260","totalValueFC":"5260.2","currency":"USD","unitRateINR":"22061","date":"28-Aug-2024","totalValueINR":"441220","totalValueInUsd":"5260.2","indian_port":"Delhi Air","hs_no":"29333100","bill_no":"5293819","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BEIJING","supplierAddress":"RM.1201 HEPING MANSION NO.22 EAST BEIJING ROAD NANJING 210008, , CHINASDNF CHINA","customerAddress":"B-4\/160, SAFDARJUNG ENCLAVE"}]
    12-Jan-2021
    04-Sep-2024
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Acasti Completes Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104

    Details:

    GTX-104 is a clinical stage, novel formulation of nimodipine, a calcium channel blocker, being developed as IV infusion in aneurysmal subarachnoid hemorrhage patients.


    Lead Product(s): Nimodipine

    Therapeutic Area: Neurology Brand Name: GTX-104

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 25, 2024

    blank

    01

    Acasti Pharma

    Canada
    arrow
    AES 2024
    Not Confirmed

    Acasti Pharma

    Canada
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Nimodipine

    Therapeutic Area : Neurology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Acasti Completes Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104

    Details : GTX-104 is a clinical stage, novel formulation of nimodipine, a calcium channel blocker, being developed as IV infusion in aneurysmal subarachnoid hemorrhage patients.

    Brand Name : GTX-104

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    September 25, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Azurity Pharmaceuticals’ NYMALIZE® Oral Solution Approved by FDA

    Details:

    Nymalize is a clinical stage, novel formulation of nimodipine, a calcium channel blocker, approved for treating aneurysmal subarachnoid hemorrhage patients.


    Lead Product(s): Nimodipine

    Therapeutic Area: Neurology Brand Name: Nymalize

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 03, 2024

    blank

    02

    Azurity Pharma

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Azurity Pharma

    U.S.A
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Nimodipine

    Therapeutic Area : Neurology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Azurity Pharmaceuticals’ NYMALIZE® Oral Solution Approved by FDA

    Details : Nymalize is a clinical stage, novel formulation of nimodipine, a calcium channel blocker, approved for treating aneurysmal subarachnoid hemorrhage patients.

    Brand Name : Nymalize

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    September 03, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial

    Details:

    GTX-104 is a clinical stage, novel formulation of nimodipine, a calcium channel blocker, being developed as IV infusion in aneurysmal subarachnoid hemorrhage patients.


    Lead Product(s): Nimodipine

    Therapeutic Area: Neurology Brand Name: GTX-104

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 27, 2024

    blank

    03

    Acasti Pharma

    Canada
    arrow
    AES 2024
    Not Confirmed

    Acasti Pharma

    Canada
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Nimodipine

    Therapeutic Area : Neurology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial

    Details : GTX-104 is a clinical stage, novel formulation of nimodipine, a calcium channel blocker, being developed as IV infusion in aneurysmal subarachnoid hemorrhage patients.

    Brand Name : GTX-104

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    June 27, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial

    Details:

    GTX-104 is a clinical stage, novel formulation of nimodipine being developed for IV infusion in aneurysmal Subarachnoid Hemorrhage patients. It incorporates surfactant micelles as the drug carrier to solubilize nimodipine.


    Lead Product(s): Nimodipine

    Therapeutic Area: Neurology Brand Name: GTX-104

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 23, 2023

    blank

    04

    Acasti Pharma

    Canada
    arrow
    AES 2024
    Not Confirmed

    Acasti Pharma

    Canada
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Nimodipine

    Therapeutic Area : Neurology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial

    Details : GTX-104 is a clinical stage, novel formulation of nimodipine being developed for IV infusion in aneurysmal Subarachnoid Hemorrhage patients. It incorporates surfactant micelles as the drug carrier to solubilize nimodipine.

    Brand Name : GTX-104

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    October 23, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Acasti Announces $7.5 Million Private Placement Equity Financing

    Details:

    The company currently intends to use the net proceeds for clinical trial expenses to further the Phase 3 clinical trial for GTX-104, a clinical stage, novel formulation of nimodipine being developed for IV infusion in aSAH patients.


    Lead Product(s): Nimodipine

    Therapeutic Area: Neurology Brand Name: GTX-104

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Undisclosed

    Deal Size: $7.5 million Upfront Cash: Undisclosed

    Deal Type: Private Placement September 26, 2023

    blank

    05

    Acasti Pharma

    Canada
    arrow
    AES 2024
    Not Confirmed

    Acasti Pharma

    Canada
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Nimodipine

    Therapeutic Area : Neurology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : $7.5 million

    Deal Type : Private Placement

    DEALS_DEV arrow-down

    Acasti Announces $7.5 Million Private Placement Equity Financing

    Details : The company currently intends to use the net proceeds for clinical trial expenses to further the Phase 3 clinical trial for GTX-104, a clinical stage, novel formulation of nimodipine being developed for IV infusion in aSAH patients.

    Brand Name : GTX-104

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    September 26, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients

    Details:

    GTX-104 is a clinical stage, novel formulation of nimodipine being developed for IV infusion in aneurysmal Subarachnoid Hemorrhage patients. It incorporates surfactant micelles as the drug carrier to solubilize nimodipine.


    Lead Product(s): Nimodipine

    Therapeutic Area: Neurology Brand Name: GTX-104

    Study Phase: Phase IProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 10, 2023

    blank

    06

    Acasti Pharma

    Canada
    arrow
    AES 2024
    Not Confirmed

    Acasti Pharma

    Canada
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Nimodipine

    Therapeutic Area : Neurology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-10...

    Details : GTX-104 is a clinical stage, novel formulation of nimodipine being developed for IV infusion in aneurysmal Subarachnoid Hemorrhage patients. It incorporates surfactant micelles as the drug carrier to solubilize nimodipine.

    Brand Name : GTX-104

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    July 10, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Ca...

    Details:

    GTX-104 is a clinical stage, novel formulation of nimodipine being developed for IV infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients. It incorporates surfactant micelles as the drug carrier to solubilize nimodipine.


    Lead Product(s): Nimodipine

    Therapeutic Area: Neurology Brand Name: GTX-104

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 05, 2023

    blank

    07

    Acasti Pharma

    Canada
    arrow
    AES 2024
    Not Confirmed

    Acasti Pharma

    Canada
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Nimodipine

    Therapeutic Area : Neurology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms ...

    Details : GTX-104 is a clinical stage, novel formulation of nimodipine being developed for IV infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients. It incorporates surfactant micelles as the drug carrier to solubilize nimodipine.

    Brand Name : GTX-104

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    July 05, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash...

    Details:

    GTX-104 is a clinical stage, novel formulation of nimodipine being developed for IV infusion in aSAH patients. It incorporates surfactant micelles as the drug carrier to solubilize nimodipine.


    Lead Product(s): Nimodipine

    Therapeutic Area: Neurology Brand Name: GTX-104

    Study Phase: Phase IProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 08, 2023

    blank

    08

    Acasti Pharma

    Canada
    arrow
    AES 2024
    Not Confirmed

    Acasti Pharma

    Canada
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Nimodipine

    Therapeutic Area : Neurology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements ...

    Details : GTX-104 is a clinical stage, novel formulation of nimodipine being developed for IV infusion in aSAH patients. It incorporates surfactant micelles as the drug carrier to solubilize nimodipine.

    Brand Name : GTX-104

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    May 08, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to...

    Details:

    GTX-104 is a clinical stage, novel formulation of nimodipine being developed for IV infusion in aSAH patients. It incorporates surfactant micelles as the drug carrier to solubilize nimodipine.


    Lead Product(s): Nimodipine

    Therapeutic Area: Neurology Brand Name: GTX-104

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 04, 2023

    blank

    09

    Acasti Pharma

    Canada
    arrow
    AES 2024
    Not Confirmed

    Acasti Pharma

    Canada
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Nimodipine

    Therapeutic Area : Neurology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon ...

    Details : GTX-104 is a clinical stage, novel formulation of nimodipine being developed for IV infusion in aSAH patients. It incorporates surfactant micelles as the drug carrier to solubilize nimodipine.

    Brand Name : GTX-104

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    April 04, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Acasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101

    Details:

    GTX-104 is a novel formulation of nimodipine for IV infusion to treat patients suffering from Subarachnoid Hemorrhage, Acasti recently reported positive results for a pharmacokinetic (PK) study, with intravenous GTX-104 meeting all endpoints.


    Lead Product(s): Nimodipine

    Therapeutic Area: Neurology Brand Name: GTX-104

    Study Phase: Phase IProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 14, 2022

    blank

    10

    Acasti Pharma

    Canada
    arrow
    AES 2024
    Not Confirmed

    Acasti Pharma

    Canada
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Nimodipine

    Therapeutic Area : Neurology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Acasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101

    Details : GTX-104 is a novel formulation of nimodipine for IV infusion to treat patients suffering from Subarachnoid Hemorrhage, Acasti recently reported positive results for a pharmacokinetic (PK) study, with intravenous GTX-104 meeting all endpoints.

    Brand Name : GTX-104

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    June 14, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDF Dossiers

    read-more
    read-more

    01

    Biophore India Pharmaceuticals Pvt ...

    India
    arrow
    iPHEX India
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : India

    Nimodipine

    Brand Name :

    Dosage Form : Tablet

    Dosage Strength : 30MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : India

    Biophore

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Alkem Laboratories

    India
    AES 2024
    Not Confirmed
    arrow

    Alkem Laboratories

    India
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : USA

    NIMODIPINE

    Brand Name : NIMODIPINE

    Dosage Form : SOLUTION;ORAL

    Dosage Strength : 30MG/5ML

    Packaging :

    Approval Date :

    Application Number : 213409

    Regulatory Info :

    Registration Country : USA

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Avet Pharmaceuticals

    U.S.A
    AES 2024
    Not Confirmed
    arrow

    Avet Pharmaceuticals

    U.S.A
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : RX

    Registration Country : USA

    NIMODIPINE

    Brand Name : NIMODIPINE

    Dosage Form : CAPSULE;ORAL

    Dosage Strength : 30MG

    Packaging :

    Approval Date : 2007-05-02

    Application Number : 77811

    Regulatory Info : RX

    Registration Country : USA

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Bayer AG

    Germany
    AES 2024
    Not Confirmed
    arrow

    Bayer AG

    Germany
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Germany
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Italy

    Nimodipine

    Brand Name : Nimotop

    Dosage Form :

    Dosage Strength : Gtt Os 25 Ml 30 Mg/0.75 Ml  

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Italy

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Bayer AG

    Germany
    AES 2024
    Not Confirmed
    arrow

    Bayer AG

    Germany
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Germany
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Originator

    Registration Country : South Africa

    Nimodipine

    Brand Name : Nimotop Iv 50Ml

    Dosage Form : INJ

    Dosage Strength : 10mg/50ml

    Packaging : 50X1mg/50ml

    Approval Date :

    Application Number :

    Regulatory Info : Originator

    Registration Country : South Africa

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    DOC Generici

    Italy
    AES 2024
    Not Confirmed
    arrow

    DOC Generici

    Italy
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Italy
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Italy

    Nimodipine

    Brand Name : Nimodipine

    Dosage Form :

    Dosage Strength : Gtt Os 25 Ml 30 Mg/0.75 Ml  

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Italy

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Yangtze River Pharmaceutical Group

    China
    AES 2024
    Not Confirmed
    arrow

    Yangtze River Pharmaceutical Group

    China
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : China

    Nimodipine

    Brand Name :

    Dosage Form : Injection

    Dosage Strength : 4MG

    Packaging : 20mL:4mgx2amps

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : China

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Country
    AES 2024
    Not Confirmed
    arrow

    Country
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Country
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Sweden

    nimodipine

    Brand Name : Nimotop

    Dosage Form : FILM COATED PILL

    Dosage Strength : 30 MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Sweden

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Country
    AES 2024
    Not Confirmed
    arrow

    Country
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Country
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Italy

    Nimodipine

    Brand Name : Nimotop

    Dosage Form :

    Dosage Strength : 36 Cpr Riv 30 Mg  

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Italy

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Country
    AES 2024
    Not Confirmed
    arrow

    Country
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Country
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Spain

    Nimodipine

    Brand Name : Remontal Nimodipine 30Mg 100 Tablets Recub Pel

    Dosage Form : Tablet

    Dosage Strength : 30 Mg/Tablet

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Spain

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    DRUG PRODUCT COMPOSITIONS

    Do you need Business Intel? Ask us

    DOSAGE - SOLUTION;ORAL - 3MG/ML **Federal Reg...DOSAGE - SOLUTION;ORAL - 3MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    USFDA APPLICATION NUMBER - 203340

    read-more

    DOSAGE - SOLUTION;ORAL - 6MG/ML

    USFDA APPLICATION NUMBER - 203340

    read-more

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Coating Systems & Additives

    read-more
    read-more

    Fillers, Diluents & Binders

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Topical

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Granulation

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Vegetarian Capsules

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Soft Gelatin

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    APIs

    read-more
    read-more
    United_States_of_America.png
    Nimodipine (1 kg) API needed in the U.S.A [ENA20113]
    A company that deals in the distribution of active ingredients is looking for suppliers Nimodipine (1 kg) API for development purposes. The suppliers must support this enquiry with USDMF & CoA.
    27 Jul 2024

    Reply

    27 Jul 2024

    Reply text-arrow

    Reply Comment (2)

    27 Jul 2024

    unitedkingdom_new.png
    Nimodipine (1 kg) API needed in the United Kingdom [ENA17900]
    A company that deals in the distribution of APIs and finished formulations is looking for suppliers of Nimodipine (1 kg) API for development purposes. The suppliers must support this enquiry with CEP & CoA.
    28 Aug 2023

    Reply

    28 Aug 2023

    Reply text-arrow

    Reply Comment (5)

    28 Aug 2023

    india-flag.png
    USP/ BP Grade Nimodipine (5 kg) API needed in India [ENA17806]
    A company that deals in various pharmaceutical products is looking for suppliers of USP/ BP Grade Nimodipine (5 kg) API for commercial purposes. The suppliers must support this enquiry with CoA.
    12 Aug 2023

    Reply

    12 Aug 2023

    Reply text-arrow

    Reply Comment (6)

    12 Aug 2023

    United_States_of_America.png
    Nimodipine (100 g) API needed in the United States [ENA17761]
    A company that focuses on research, development and commercialization of technologies for peripheral nerve regeneration and repair is looking for suppliers of Nimodipine (100 g) API for development purposes. The suppliers must support this enquiry with USDMF, GMP & CoA.
    05 Aug 2023

    Reply

    05 Aug 2023

    Reply text-arrow

    Reply Comment (6)

    05 Aug 2023

    Ireland.png
    Various APIs needed in Ireland [ENA17329]
    A company that focuses on developing innovative, clinically proven technologies and solutions for the treatment of neurovascular diseases is looking for suppliers of Various APIs for development purposes. The suppliers must support this enquiry with CoA. 1. Nimodipine API 2. Adenosine API 3. Alteplase API 4. Urokinase API
    16 Jun 2023

    Reply

    16 Jun 2023

    Reply text-arrow

    Reply Comment (5)

    16 Jun 2023

    Spain_new.png
    Nimodipine (MOQ) API needed in Spain [ENA13404]
    A company that deals in the development & production of modern innovative products based on organic, synthetic and herbal compounds is looking for suppliers of Nimodipine (MOQ) API for development purpose. The suppliers must support this enquiry with DMF or CEP & CoA.
    22 Apr 2022

    Reply

    22 Apr 2022

    Reply text-arrow

    Reply Comment (9)

    22 Apr 2022

    india-flag.png
    BP Grade Nimodipine (25 kg) API needed in India [ENA09788]
    A company that deals in a wide range of product list including generic tablets, capsules, multi-vitamins, ointments, dry-syrups, injections & veterinary formulations is looking for suppliers of BP Grade Nimodipine (25 kg) API for commercial purposes. The suppliers must support this enquiry with CoA.
    22 Feb 2021

    Reply

    22 Feb 2021

    Reply text-arrow

    Reply Comment (7)

    22 Feb 2021

    india-flag.png
    Various APIs needed in India [ENA09567]
    A WHO-GMP accredited company that deals in various finished formulations is looking for suppliers of Various APIs for development purposes. The suppliers must support this enquiry with USDMF. The final market is the US. 1. USP Grade Dopamine HCl (300 g) API 2. USP Grade Iohexol (37.75 kg) API 3. USP Grade Nitroglycerine (20 g) API 4. USP Grade Dobutamine HCl (200 g) API 5. USP Grade Ropivacaine HCl (250 g) API 6. BP Grade Nimodipine (10 g) API 7. USP Grade Sodium Bicarbonate (4.2 kg) API
    23 Jan 2021

    Reply

    23 Jan 2021

    Reply text-arrow

    Reply Comment (3)

    23 Jan 2021

    india-flag.png
    Levodopa & Nimodipine APIs needed in India [ENA06016]
    A company specialized in oral solids, oral liquids, semi-solids, and injectable formulation is looking for suppliers of APIs. The supplier must support this enquiry with CoA. 1. IP grade Levodopa 2. BP grade Nimodipine
    11 Dec 2019

    Reply

    11 Dec 2019

    Reply text-arrow

    Reply Comment (3)

    11 Dec 2019

    PharmaCompass
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    US Patents

    read-more
    read-more

    01

    AZURITY

    NIMODIPINE

    arrow
    AES 2024
    Not Confirmed

    AZURITY

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Patent Expiration Date : 2038-04-16

    NIMODIPINE

    US Patent Number : 10576070

    Drug Substance Claim :

    Drug Product Claim : Y

    Application Number : 203340

    Patent Use Code : U-2804

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2038-04-16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    AZURITY

    NIMODIPINE

    arrow
    AES 2024
    Not Confirmed

    AZURITY

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Patent Expiration Date : 2038-04-16

    NIMODIPINE

    US Patent Number : 11207306

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 203340

    Patent Use Code : U-2804

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2038-04-16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    AZURITY

    NIMODIPINE

    arrow
    AES 2024
    Not Confirmed

    AZURITY

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Patent Expiration Date : 2024-05-14

    NIMODIPINE

    US Patent Number : 8517997

    Drug Substance Claim :

    Drug Product Claim : Y

    Application Number : 203340

    Patent Use Code :

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2024-05-14

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    AZURITY

    NIMODIPINE

    arrow
    AES 2024
    Not Confirmed

    AZURITY

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Patent Expiration Date : 2038-04-16

    NIMODIPINE

    US Patent Number : 11806338

    Drug Substance Claim :

    Drug Product Claim : Y

    Application Number : 203340

    Patent Use Code :

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2038-04-16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    AZURITY

    NIMODIPINE

    arrow
    AES 2024
    Not Confirmed

    AZURITY

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Patent Expiration Date : 2038-04-16

    NIMODIPINE

    US Patent Number : 11413277

    Drug Substance Claim :

    Drug Product Claim : Y

    Application Number : 203340

    Patent Use Code : U-2804

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2038-04-16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    AZURITY

    NIMODIPINE

    arrow
    AES 2024
    Not Confirmed

    AZURITY

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Patent Expiration Date : 2038-04-16

    NIMODIPINE

    US Patent Number : 10342787

    Drug Substance Claim :

    Drug Product Claim : Y

    Application Number : 203340

    Patent Use Code : U-2804

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2038-04-16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Health Canada Patents

    read-more
    read-more

    01

    Nimodipine
    arrow
    AES 2024
    Not Confirmed

    Country
    arrow
    AES 2024
    Not Confirmed

    Patent Expiration Date : 2004-04-14

    Date Granted :

    Nimodipine

    Brand Name :

    Patent Number : 1220424

    Filing Date :

    Strength per Unit :

    Dosage Form :

    Human Or VET :

    Route of Administration :

    Patent Expiration Date : 2004-04-14

    Date Granted :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    USP

    read-more
    read-more

    01

    USP

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    02

    USP

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    03

    USP

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    USP

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Nimodipine (125 mg)

    CAS Number : 66085-59-4

    Quantity Per Vial :

    Price ($) : 230

    Catalog Number : 1463858

    Current Lot : R061B0

    Previous Lot : F0F203 (31-MAY-2017)

    NDC Code :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search